Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain

Hideya Kokubun, Motohiro Matoba, Miyoko Okazaki, Sumio Hoka, Kazuo Yago

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Occasionally, pain control with the fentanyl patch may lead to overdose at an initial dose of 2.5 mg, as well as during dose increase from 2.5 to 5.0 mg. Respiratory depression and other adverse drug reactions associated with fentanyl overdose have been observed in several of our patients. We developed a procedure for applying one-half of the fentanyl patch formulations and evaluated the new mode of application by examining the fentanyl concentration in 32 patients with cancer-related pain who had been using the fentanyl patch for pain control. While some patients were treated with the full-sized 2.5-, 5.0-, or 7.5-mg formulations, others were treated with the half-sized 2.5-mg formulation. The fentanyl patch was equally divided by drawing a line on the side on which the product name and dose were written. Tegaderm was applied to the patient's skin, and after detaching from the protective liner, half of the patch was applied to overlap Tegaderm along the line and the other half applied directly to the skin. Blood samples were collected 48.72 h after patch application. The mean serum concentration of fentanyl given in the half-sized 2.5-mg formulation was 0.286 ng/ml, which was approximately one-half of the concentration of the full-sized 2.5-mg formulation, 0.544 ng/ml. Therefore the 2.5-mg fentanyl patch, applied using the one-half procedure we developed, is clinically useful.

Original languageEnglish
Pages (from-to)447-450
Number of pages4
JournalYakugaku Zasshi
Volume128
Issue number3
DOIs
Publication statusPublished - Mar 1 2008

Fingerprint

Fentanyl
Pain
Skin
Cancer Pain
Drug-Related Side Effects and Adverse Reactions
Respiratory Insufficiency
Names
Serum

All Science Journal Classification (ASJC) codes

  • Molecular Medicine

Cite this

Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain. / Kokubun, Hideya; Matoba, Motohiro; Okazaki, Miyoko; Hoka, Sumio; Yago, Kazuo.

In: Yakugaku Zasshi, Vol. 128, No. 3, 01.03.2008, p. 447-450.

Research output: Contribution to journalArticle

Kokubun, Hideya ; Matoba, Motohiro ; Okazaki, Miyoko ; Hoka, Sumio ; Yago, Kazuo. / Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain. In: Yakugaku Zasshi. 2008 ; Vol. 128, No. 3. pp. 447-450.
@article{f3f8a0e8b493418280081579dc373c71,
title = "Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain",
abstract = "Occasionally, pain control with the fentanyl patch may lead to overdose at an initial dose of 2.5 mg, as well as during dose increase from 2.5 to 5.0 mg. Respiratory depression and other adverse drug reactions associated with fentanyl overdose have been observed in several of our patients. We developed a procedure for applying one-half of the fentanyl patch formulations and evaluated the new mode of application by examining the fentanyl concentration in 32 patients with cancer-related pain who had been using the fentanyl patch for pain control. While some patients were treated with the full-sized 2.5-, 5.0-, or 7.5-mg formulations, others were treated with the half-sized 2.5-mg formulation. The fentanyl patch was equally divided by drawing a line on the side on which the product name and dose were written. Tegaderm was applied to the patient's skin, and after detaching from the protective liner, half of the patch was applied to overlap Tegaderm along the line and the other half applied directly to the skin. Blood samples were collected 48.72 h after patch application. The mean serum concentration of fentanyl given in the half-sized 2.5-mg formulation was 0.286 ng/ml, which was approximately one-half of the concentration of the full-sized 2.5-mg formulation, 0.544 ng/ml. Therefore the 2.5-mg fentanyl patch, applied using the one-half procedure we developed, is clinically useful.",
author = "Hideya Kokubun and Motohiro Matoba and Miyoko Okazaki and Sumio Hoka and Kazuo Yago",
year = "2008",
month = "3",
day = "1",
doi = "10.1248/yakushi.128.447",
language = "English",
volume = "128",
pages = "447--450",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "公益社団法人 日本薬学会",
number = "3",

}

TY - JOUR

T1 - Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain

AU - Kokubun, Hideya

AU - Matoba, Motohiro

AU - Okazaki, Miyoko

AU - Hoka, Sumio

AU - Yago, Kazuo

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Occasionally, pain control with the fentanyl patch may lead to overdose at an initial dose of 2.5 mg, as well as during dose increase from 2.5 to 5.0 mg. Respiratory depression and other adverse drug reactions associated with fentanyl overdose have been observed in several of our patients. We developed a procedure for applying one-half of the fentanyl patch formulations and evaluated the new mode of application by examining the fentanyl concentration in 32 patients with cancer-related pain who had been using the fentanyl patch for pain control. While some patients were treated with the full-sized 2.5-, 5.0-, or 7.5-mg formulations, others were treated with the half-sized 2.5-mg formulation. The fentanyl patch was equally divided by drawing a line on the side on which the product name and dose were written. Tegaderm was applied to the patient's skin, and after detaching from the protective liner, half of the patch was applied to overlap Tegaderm along the line and the other half applied directly to the skin. Blood samples were collected 48.72 h after patch application. The mean serum concentration of fentanyl given in the half-sized 2.5-mg formulation was 0.286 ng/ml, which was approximately one-half of the concentration of the full-sized 2.5-mg formulation, 0.544 ng/ml. Therefore the 2.5-mg fentanyl patch, applied using the one-half procedure we developed, is clinically useful.

AB - Occasionally, pain control with the fentanyl patch may lead to overdose at an initial dose of 2.5 mg, as well as during dose increase from 2.5 to 5.0 mg. Respiratory depression and other adverse drug reactions associated with fentanyl overdose have been observed in several of our patients. We developed a procedure for applying one-half of the fentanyl patch formulations and evaluated the new mode of application by examining the fentanyl concentration in 32 patients with cancer-related pain who had been using the fentanyl patch for pain control. While some patients were treated with the full-sized 2.5-, 5.0-, or 7.5-mg formulations, others were treated with the half-sized 2.5-mg formulation. The fentanyl patch was equally divided by drawing a line on the side on which the product name and dose were written. Tegaderm was applied to the patient's skin, and after detaching from the protective liner, half of the patch was applied to overlap Tegaderm along the line and the other half applied directly to the skin. Blood samples were collected 48.72 h after patch application. The mean serum concentration of fentanyl given in the half-sized 2.5-mg formulation was 0.286 ng/ml, which was approximately one-half of the concentration of the full-sized 2.5-mg formulation, 0.544 ng/ml. Therefore the 2.5-mg fentanyl patch, applied using the one-half procedure we developed, is clinically useful.

UR - http://www.scopus.com/inward/record.url?scp=40449142831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449142831&partnerID=8YFLogxK

U2 - 10.1248/yakushi.128.447

DO - 10.1248/yakushi.128.447

M3 - Article

C2 - 18311065

AN - SCOPUS:40449142831

VL - 128

SP - 447

EP - 450

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 3

ER -